Bexion Pharmaceuticals

Bexion Pharmaceuticals is a private, clinical-stage biotech advancing BXQ-350, a first-in-class biologic designed to modulate sphingolipid metabolism. Its dual mechanism aims to create an anti-tumor environment by altering key lipid signaling molecules while also demonstrating neuroprotective properties to address chemotherapy-induced peripheral neuropathy. The company has completed enrollment in a Phase 1b/2a trial in first-line metastatic colorectal cancer (mCRC) and a proof-of-concept study in CIPN, positioning it to address significant unmet needs in oncology supportive care.

Sphingolipid metabolism modulation using a biologic composed of the protein Saposin C (SapC) and the phospholipid DOPS. The platform is designed to shift the balance of key sphingolipids (decreasing pro-cancer S1P, increasing pro-apoptotic ceramide) to treat cancer and neuropathic pain.

In mCRC, BXQ-350 faces competition from numerous targeted therapies, immunotherapies, and standard chemotherapies. Its differentiation lies in its unique mechanism and potential neuroprotective benefit. In CIPN, the competitive landscape is sparse with no approved disease-modifying therapies, representing a white space opportunity if clinical efficacy is proven.